Press Releases

Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...

Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on...

Data from the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Provide Valuable Information About the Treatment of Patients with Advanced Renal Cell Carcinoma and Certain Types of Advanced...

Final Pre-Specified Overall Survival Analysis from the Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation NUTLEY, N.J., May 23,...

Initiative Features Compelling Stories Celebrating That People are "Made of More" Than Their Head and Neck Cancer Diagnosis, Along With Resources to Help People Impacted Find Support and Community...